Downloadable slideset with highlights from key gastrointestinal cancers as presented at 2022 ESMO World Congress on Gastrointestinal Cancer, from Clinical Care Options (CCO)
Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)
Clinical Care Options (CCO): Experts review key data for gastric, rectal, liver, hepatobiliary tract, and pancreas cancers from the 2022 ASCO Gastrointestinal Cancers Symposium and the ASCO Plenary Series
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.